Lidocain Aguettant (Lidocaine Hydrochloride)

Lidocaine blocks voltage‑gated sodium channels in neuronal membranes, preventing the rapid influx of sodium ions needed for depolarization. This reversible inhibition stops the generation and propagation of nerve impulses, producing a temporary loss of sensation in the targeted area.

The specific dose is determined by the prescribing clinician based on the procedure, patient weight, and site of administration. Standard practice follows established maximum recommended limits for infiltration, intradermal or intravenous regional techniques, and the prescriber sets the exact amount.

Safety data are limited; lidocaine crosses the placenta and may be present in breast milk. Use is permitted only when the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by the treating physician.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with other amide‑type agents such as bupivacaine, lidocaine has a faster onset but a shorter duration of action, making it suitable for procedures requiring rapid anesthesia and quick recovery. Its toxicity profile is well‑characterized, and it is less cardiotoxic than some longer‑acting alternatives.

Store at ambient temperature, preferably below 25 °C, in the original sealed container. Protect from direct sunlight, moisture and extreme temperatures. Do not freeze. Inspect the solution for particulate matter or discoloration before use and discard if any abnormalities are observed.

The product is supplied as a sterile solution for injection. It can be administered by infiltration into the tissue surrounding the surgical site, intradermally for diagnostic or minor procedures, or intravenously as part of a regional (Bier) block. Administration technique follows standard aseptic practices and the dosage recommended by the prescriber.

Serious adverse events include systemic toxicity manifesting as central nervous system seizures, cardiac arrhythmias, hypotension, methemoglobinemia, and severe allergic reactions such as anaphylaxis. These risks increase with excessive dosing, rapid intravascular injection, or when combined with interacting medications, and require immediate medical intervention.

Individuals with a known hypersensitivity to lidocaine or other amide‑type local anesthetics should avoid this product. Caution is also advised for patients with severe cardiac conduction disorders, uncontrolled epilepsy, or those receiving medications that significantly raise lidocaine plasma levels. Use is contraindicated in such cases unless an alternative has been evaluated and approved by a qualified clinician.